Overview

The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).

Eligibility

Inclusion Criteria for Part A and B

• Participant must be 18-65 years of age
• Participant must be overtly healthy

Inclusion Criteria for Part C

• Participant must be 40-75 years of age
• Confirmed diagnoses of T2DM

Exclusion Criteria for Part A and B

• History of hypotension, syncope, or orthostatic intolerance
• Systolic blood pressure \>140 millimeters of mercury (mmHg) or diastolic blood pressure \>90 mmHg

Exclusion Criteria for Part C

• Hemoglobin A1c (HbA1c) \>10% within the last 3 months
• History of hypotension, syncope, or orthostatic intolerance
• Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg